5 Best Low Leverage Stocks to Buy

3. Globus Medical, Inc. (NYSE:GMED)

On May 8, 2026, Needham raised the firm’s price target on Globus Medical, Inc. (NYSE:GMED) to $117 from $114 while maintaining a Buy rating on the shares.

Meanwhile, Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Globus Medical, Inc. (NYSE:GMED) to $103 from $104 while maintaining an Overweight rating on the shares. The firm noted that Globus Medical delivered Q1 revenue and EPS ahead of both its own estimates and broader consensus expectations.

Globus Medical, Inc. (NYSE:GMED) reported Q1 EPS of $1.12, versus the consensus estimate of 92c. Revenue totaled $759.85M, compared to the consensus estimate of $740.83M. President and CEO Keith Pfeil said the company began 2026 with strong momentum, highlighted by 27% overall revenue growth and record first-quarter earnings. Organic revenue increased more than 13%, supported by market share gains and strong procedural volumes in the core spine business, while the Enabling Technologies segment continued expanding its customer base. Pfeil added that manufacturing and supply chain execution, structural cost actions, and operating leverage from higher volumes contributed to margin expansion that outpaced revenue growth. The company said its strategic focus remains centered on improving surgical outcomes through an integrated ecosystem that combines patient selection, surgical techniques, implants, and enabling technologies.

Globus Medical also raised its FY26 EPS outlook to $4.70-$4.80 from a prior range of $4.40-$4.50. Consensus estimates were $4.47. The company reaffirmed its FY26 revenue guidance of $3.18B-$3.22B, compared to consensus expectations of $3.2B.

Globus Medical, Inc. (NYSE:GMED) develops and commercializes musculoskeletal healthcare solutions and surgical technologies in the United States and international markets.